Ascenta Therapeutics is a privately-held, clinical stage biopharmaceutical company dedicated to the discovery and development of new medicines to treat cancer.  Ascenta’s current focus is a portfolio of novel, orally-active, small molecule drugs that restore the natural potential for cancer cells to undergo cell death (apoptosis).

June 1, 2009:
Ascenta Therapeutics Announces Presentation of Promising Results from Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting

May 26th, 2009:
Ascenta Therapeutics Announces Multiple Presentations on AT-101 at the 2009 ASCO Annual Meeting

April 21, 2009:
Ascenta Therapeutics Announces Results of Preclinical Evaluation of AT-406 in Multiple Cancer Models and AT-101 in Neuroblastoma Cell Lines

Corporate Fact Sheet

• 2009

Ascenta is developing drugs that target three distinct pathways to cancer cell apoptosis (cell death):

• AT-101 a pan Bcl-2 inhibitor
• AT-406 a multi-IAP antagonist
• HDM2-p53 inhibitor

In Phase I and Phase II trials, AT-101 has demonstrated activity as a single-agent and in combination with other anticancer therapies in several cancers, including: B-cell malignancies (CLL and NHL), esophageal cancer, glioma, hormone-refractory prostate cancer (HRPC), non-small cell lung cancer (NSCLC), and small cell lung cancer (SCLC). A potential lead indication for AT-101 is in treating patients with HRPC. Initial findings from an ongoing Phase II study of AT-101 in combination with docetaxel (Taxotere®) in patients with chemotherapy-naïve and docetaxel refractory HRPC demonstrated that AT-101 can be safely administered and clinical responses, based on both PSA and tumor shrinkage have been observed.

Learn More >>